A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Abstract

Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).

Keywords

Affiliated Institutions

• Cliniques Universitaires Saint-Luc BE
• Université Paris Cité FR
• Antwerp University Hospital BE
• Inova Fairfax Hospital US
• Pinnacle Clinical Research US
• Saarland University DE
• Newcastle University GB
• National Institute for Health Research GB
• Virginia Commonwealth University US
• Madrigal Pharmaceuticals (United States) US
• Istituti di Ricovero e Cura a Carattere Scientifico IT
• University of Oxford GB
• University of Newcastle Australia AU
• Icahn School of Medicine at Mount Sinai US
• Duke University Health System US
• University Medical Center US
• Texas Research Institute US
• University of Chicago US
• Clinical Research Institute US
• Inserm FR
• University Medical Center of the Johannes Gutenberg University Mainz DE
• University Hospitals Birmingham NHS Foundation Trust GB
• Centre de Recherche sur l'Inflammation FR
• Vall d'Hebron Institut de Recerca ES
• Universitat Autònoma de Barcelona ES
• Hebron University PS
• University of California, San Diego US
• University of Birmingham GB
• Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas ES
• Johannes Gutenberg University Mainz DE
• Casa Sollievo della Sofferenza IT
• Klinikum St. Georg DE
• Centre de Recherche des Cordeliers FR
• Arizona Liver Health US
• Mayo Clinic in Arizona US
• Houston Methodist US
• Hôpital Beaujon FR
• Banner - University Medical Center Tucson US

Related Publications